NCT00369291终止1 期
CPG 7909 Oligodeoxynucleotides (ODNS) After Autologous Transplantation to Enhance Immune Reconstitution
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 终止
- 入组人数
- 19
- 试验地点
- 1
- 主要终点
- Enhanced immune function as measured by response to keyhole limpet hemocyanin and tetanus toxoid
研究概览
简要总结
RATIONALE: Giving CpG 7909 after an autologous stem cell transplant may make a stronger immune response and prevent or delay the recurrence of cancer.
PURPOSE: This phase I trial is studying the side effects and best dose of CpG 7909 in treating patients who have undergone autologous stem cell transplant.
详细描述
OBJECTIVES:
Primary
- Determine whether CpG 7909 enhances immune function, as measured by the response to keyhole limpet hemocyanin (neo-antigen) and tetanus toxoid (memory antigen), in patients who have undergone autologous stem cell transplantation.
Secondary
- Determine if dose escalation of CpG 7909, within a range of previously tested safe doses of CpG 7909, impacts upon the primary immune readouts.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients must have undergone autologous transplantation for non-Hodgkin's lymphoma (NHL), Hodgkin's disease, acute myelogenous leukemia (AML), germ cell tumors, or multiple myeloma.
- •Patients must be eligible for and consent to participate in study MT1999 06 - Vaccination with tetanus toxoid and Keyhole Limpet Hemocyanin (KLH) to assess antigen specific immune responses (BB-IND 10430).
- •Patients will be eligible to receive CpG 7909 and vaccines on or after day 60 post transplant. No patients are eligible for this protocol beyond day 74 post transplant. Therefore, all patients will start therapy on this protocol between days 60-74 post transplant to allow for patient scheduling flexibility.
- •Patients must have engraftment and be independent of transfusion support or growth factor support.
- •Patients must not have received platelet or red-cell transfusions in the previous week.
- •Patients must have been continuously off all growth factors for at least 1 week.
- •Unsupported counts must be:
- •platelets ≥ 50,000/ml
- •Hgb ≥ 9 gm/ul
- •Absolute neutrophil count ≥ 1000/µL
- •Absolute lymphocyte count ≥ 500/µL
- •Patients must have a current performance status of 0-1 (Eastern Cooperative Oncology Group) or 70-100% (Karnofsky.
- •Patients must be afebrile, off antibiotics therapeutic (not prophylactic), and free of evidence of active infection. Patients must be off intravenous (IV) hyperalimentation and IV fluids.
- •Minimum laboratory values within 2 weeks of entry: Creatinine ≤ 2.0 mg/dl or CrCl ≥ 50 ml/min, Bilirubin, ALT ≤ 2 x normal
- •Age >18 years
- •Patients receiving or scheduled to receive planned radiation therapy, growth factor therapy, or steroid therapy during the study period will be ineligible. Patients must have completed all planned post-transplant radiation therapy if applicable.
- •Patients must be able to give written informed consent and agree to comply with the study parameters
- •Patients must agree to use contraception during the study.
排除标准
- •Patients with one or more of the following:
- •Active infection, or fever >38.2˚C
- •Significant nonmalignant disease including documented HIV infection, uncontrolled hypertension (diastolic blood presses >115 mmHg), unstable angina, congestive heart failure (NY Class II), poorly controlled diabetes, coronary angioplasty within 6 months, myocardial infarction with the last 6 months, or uncontrolled atrial or ventricular cardiac arrhythmias.
- •Hematopoietic growth factors administered within 1 week of study entry.
- •Expected to require additional cytotoxic therapy within 30 days of study
- •Receiving other post-transplant investigational agents
- •Patients with a history of autoimmune diseases will be ineligible for this protocol
- •It is unknown whether CpG 7909 may exacerbate autoimmune disorders by its immunomodulatory effects. Therefore, subjects with a history of autoimmune disease should not receive CpG
- •Controlled thyroid disease is permissible.
- •Systemic corticosteroids or other immunosuppressants
- •Pregnant or lactating (It is unlikely and probably unwise that a women of childbearing potential become pregnant this early after transplant, however; if any suspicion, a pregnancy test should be done)
- •Not meeting one or more of the eligibility criteria, as listed above
研究组 & 干预措施
CpG 7909
Experimental
Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
干预措施: tetanus toxoid (Biological)
CpG 7909
Experimental
Patients treated with CpG 7909 oligodeoxynucleotides (ODNs) after autologous transplantation to enhance immune reconstitution.
干预措施: keyhole limpet hemocyanin (Biological)
结局指标
主要结局
Enhanced immune function as measured by response to keyhole limpet hemocyanin and tetanus toxoid
时间窗: 1 Month after vaccine
anti-KLH IgG
次要结局
- Impact of dose escalation of CpG 7909 on primary immune readouts(At study completion)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Dose Finding Study of CpG in Patients With Chronic Lymphocytic Leukemia Who Have Been Previously TreatedChronic Lymphocytic LeukemiaNCT00233506University of Iowa41
Unknown
1 期
Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single VaccinationChronic Myeloid LeukemiaNon Hodgkin's LymphomaHodgkin's DiseaseAplastic AnemiaMultiple MyelomaAcute Myeloid LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic SyndromeNCT02007811University of Erlangen-Nürnberg Medical School15
已完成
1 期
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin LymphomaNodal Marginal Zone LymphomaRecurrent Grade 1 Follicular LymphomaRecurrent Grade 3 Follicular LymphomaRecurrent Mantle Cell LymphomaExtranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid TissueRecurrent Grade 2 Follicular LymphomaWaldenstrom MacroglobulinemiaRecurrent Marginal Zone LymphomaAdult Non-Hodgkin LymphomaRecurrent Adult Diffuse Large Cell LymphomaSplenic Marginal Zone LymphomaRecurrent Small Lymphocytic LymphomaNCT00438880Mayo Clinic38
Unknown
不适用
Pre-emptive Immunomodulation After Allogeneic Stem Cell Transplantation in AMLAMLNCT02888522University Hospital, Caen60
已完成
1 期
Administration of Anti-CD19-chimeric-antigen-receptor-transduced T Cells From the Original Transplant Donor to Patients With Recurrent or Persistent B-cell Malignancies After Allogeneic Stem Cell TransplantationLymphoma, Non-hodgkinsLeukemia, B-cellLymphoma, B-CellLymphoma, HodgkinsNCT01087294National Cancer Institute (NCI)85